A Preliminary Study on Enhancing the Efficacy of Sorafenib by Silencing STAT3 Gene in SK-Hep1 Cells

doi:10.13523/j.cb.20171202

China Biotechnology

2017, Vol. 37

Issue (12): 8-13 DOI: 10.13523/j.cb.20171202

Orginal Article

A Preliminary Study on Enhancing the Efficacy of Sorafenib by Silencing STAT3 Gene in SK-Hep1 Cells

Lin-na XIE^1,²,Yan-hua ZENG²,Huo-zhao KE¹,Wen-sheng HE¹,Min ZHENG²,De-xin LIN^2*(

)

1 Department of Food and Bioengineering, Fujian Vocational College of Bioengineering,Fuzhou 350003, China
2 College of Basic Medical Sciences,Fujian Medical University, Fuzhou　350108, China

Download:

HTML

PDF(576KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract Objective:

To determine the effect of STAT3 on sorafenib resistance in hepatocarcinoma cell SK-Hep1, and the role of STAT3 gene silencing on enhancing the efficacy of sorafenib in liver cancer.

Methods:

STAT3 gene was knocked down by short hairpin RNA based gene-silencing technology in SK-Hep1 cells. The cell proliferation and the sensitivity to sorafenib were detected by CCK8 assay. The expression levels of STAT3, p-STAT3(Y705),p-STAT3(S727)and its downstream proteins were detected by Western blot.

Results:

STAT3 knockdown cell line SK-Hep1-shSTAT3 was successfully constructed. In these cells, the level of STAT3 expression was decreased; the cell proliferation was significantly suppressed.Sorafenib treatment reduced the level of STAT3 phosphorylation and its downstream protein CyclinD1 and Mcl-1.Sorafenib resistance was reduced in STAT3 knockdown cells.

Conclusion:

Silencing STAT3 by RNA interference can significantly suppress SK-Hep1 cell proliferation, and enhance the sensitivity of liver cancer cells to sorafenib.The data indicates that STAT3 knockdown might be a new way to improve the efficacy of sorafenibin liver cancer.

Key words： Hepatocarcinoma Sorafenib STAT3 Gene silence

Received: 18 August 2017 Published: 16 December 2017

ZTFLH:

R963

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Lin-na XIE
	Yan-hua ZENG
	Huo-zhao KE
	Wen-sheng HE
	Min ZHENG
	De-xin LIN

Cite this article:

Lin-na XIE,Yan-hua ZENG,Huo-zhao KE,Wen-sheng HE,Min ZHENG,De-xin LIN. A Preliminary Study on Enhancing the Efficacy of Sorafenib by Silencing STAT3 Gene in SK-Hep1 Cells. China Biotechnology, 2017, 37(12): 8-13.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20171202 OR https://manu60.magtech.com.cn/biotech/Y2017/V37/I12/8

Fig.1 Analysis of STAT3 and its phosphorylationin gene silencing cell SK-Hep1 by Western blot

Fig.2 Effects of different concentrations of sorafenib on STAT3 protein expression and phosphorylation modification in SK-Hep1 cells

Fig.3 Effects of sorafenib on SK-Hep1 knockdown STAT3 gene
(a) Cell growth curve of SK-Hep1-shSTAT3 and control treated by sorafenib(compared with the control group, ^* P<0.05, ^** P<0.01, n=3) (b) Cell viability change in SK-Hep1-shSTAT3 treated by different concentrations of sorafenib (compared with the control group ^** P<0.01, n=3)

Fig.4 The effect of sorafenib on the expression of STAT3 and its downstream protein Mcl-1 and CyclinD1 in SK-Hep1 cells


[1]	Wilhelm S, Carter C, Lynch M, et al.Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Reviews Drug Discovery, 2006,5(10):835-844. doi: 10.1038/nrd2130 pmid: 17016424

[2]	Llovet J M, Ricci S, Mazzaferro V, et al.Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine, 2008, 359(4):378-390. doi: 10.1056/NEJMoa0708857

[3]	Maluccio M, Covey A.Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA: A Cancer Journal for Clinicians, 2012, 62(6):394-399. doi: 10.3322/caac.21161 pmid: 23070690

[4]	Levy D E, Inghirami G.STAT3: a multifaceted oncogene. Proc Natl Acad Sci USA, 2006, 103(27):10151-10152. doi: 10.1073/pnas.0604042103 pmid: 16801534

[5]	Zimmers T A, Fishel M L, Bonetto A.STAT3 in the systemic inflammation of cancer cachexia. Seminars in Cell & Developmental Biology, 2016, 54:28-41. doi: 10.1016/j.semcdb.2016.02.009 pmid: 4867234

[6]	He G, Karin M.NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Research, 2011, 21(1):159-168. doi: 10.1038/cr.2010.183 pmid: 21187858

[7]	Sanchez A, Nagy P. Thorgeirsson S S.STAT-3 activity in chemically-induced hepatocellular carcinoma. European Journal of Cancer, 2003, 39(14):2093-2098. doi: 10.1016/S0959-8049(03)00393-9 pmid: 12957465

[8]	Moh A, Iwamoto Y, Chai G X, et al.Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery. Laboratory Investigation, 2007, 87(10):1018-1028. doi: 10.1038/labinvest.3700630 pmid: 17660847

[9]	Kiprianova I, Remy J, Milosch N, et al.Sorafenib sensitizes glioma cells to the BH3 mimetic ABT-737 by targeting MCL1 in a STAT3-dependent manner. Neoplasia, 2015, 17(7):564-573. doi: 10.1016/j.neo.2015.07.003 pmid: 26297434

[10]	Su T H, Shiau C W, Jao P, et al.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad Sci USA, 2015, 112(23):7243-7248. doi: 10.1073/pnas.1507499112 pmid: 26039995

[11]	Wang C Y, Chao T T, Tai W T, et al.Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer. Journal of Thoracic Oncology, 2014, 9(4):488-496. doi: 10.1097/JTO.0000000000000107 pmid: 24736071

[12]	Pichard D C, Cardones A R, Chu E Y, et al.Sorafenib-induced eruption mimicking erythema multiforme. JAMA Dermatology, 2016, 152(2):227-228. doi: 10.1001/jamadermatol.2015.2930 pmid: 26422655

[13]	郑敏, 谢琳娜, 曾燕华,等. CD44、CD133及EpCAM与肝癌细胞成瘤性及耐药性的相关性. 中国老年学杂志, 2015, 35(23):6668-6670.

[13]	Zheng M, Xie L N, Zeng Y H, et al. Correlation of CD44,CD133 an EpCAM with tumorigenicity and sorafenis resistance of liver cancer cells. Chinese Journal of Gerontology, 2015,35(23):6668-6670.

[14]	Rahmani M, Davis E M, Bauer C, et al.Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. The Journal of Biological Chemistry, 2005, 280(42):35217-35227. doi: 10.1074/jbc.M506551200 pmid: 16109713

[15]	Yu C, Bruzek L M, Meng X W, et al.The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene, 2005, 24(46):6861-6869. doi: 10.1038/sj.onc.1208841

[16]	Yang F, Van Meter T E, Buettner R, et al. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Molecular Cancer Therapeutics, 2008, 7(11):3519-3526. doi: 10.1158/1535-7163.MCT-08-0138 pmid: 19001435

[17]	Yang F, Brown C, Buettner R, et al.Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. Molecular Cancer Therapeutics, 2010, 9(4):953-962. doi: 10.1158/1535-7163.MCT-09-0947 pmid: 20371721

[18]	Li L, Wang H.Heterogeneity of liver cancer and personalized therapy. Cancer Letters, 2016, 379(2):191-197. doi: 10.1016/j.canlet.2015.07.018 pmid: 26213370

[19]	Hikita H, Takehara T, Shimizu S, et al.The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology, 2010, 52(4):1310-1321. doi: 10.1002/hep.23836 pmid: 20799354

[20]	Casadei Gardini A, Tenti E, Masini C, et al.Multicentric survey on dose reduction/interruption of cancer drug therapy in 12 472 patients: indicators of suspected adverse reactions. Oncotarget, 2016, 7(26):40719-40724. doi: 10.18632/oncotarget.8942 pmid: 27119511

[21]	Tae-Yong H A, Shin Hwang, KI-Myeong Moon, et al.Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression. Anticancer Res, 2015,35(4):1967-1976. pmid: 25862849

[22]	Zeynep Firtina Karagonlar, Dogukan Koc, Evin Iscan, et al.Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. Cancer Sci, 2016,107(4):407-416. doi: 10.1111/cas.12891 pmid: 26790028

[23]	Man-Hsin Hung, Wei-Tien Tai, Chung-Wai Shiau, et al.Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. World J Gastroenterol, 2014,20(41):15269-15274. doi: 10.3748/wjg.v20.i41.15269 pmid: 25386075

[1]	LIN Lu,HU Li-jun,HUANG Yi-yun,CHEN Lu,HUANG Mao,PENG Qi,HU Qin,ZHOU Lan. S100A6 Promotes Angiogenesis Through Recruiting and Activating Macrophages[J]. China Biotechnology, 2020, 40(5): 7-14.

[2]	Lu CHEN,Mao HUANG,Qi PENG,Jia-li ZHAO,Jia-qing XIE,Lu LIN,Li-jun HU,Yi-yun HUANG,Qin HU,Lan ZHOU. S100A6 Promotes Cell Proliferation of Colorectal Cancer via Upregulating IL-6 Expression of Macrophages[J]. China Biotechnology, 2019, 39(4): 1-7.

[3]	DAI Li-ting, WU Zhong-nan, HUANG Xiang, YANG Jie, ZENG Hui-lan, WANG Guo-cai, JIANG Jian-wei. *Molecular Mechanism of Inducing GLC-82 Cells Apoptosis by Ethanol Extract from Wedelia prostrate(Hook.et Arn.) Hemsl*[J]. China Biotechnology, 2017, 37(8): 1-7.

[4]	SUN Yuan-yuan, LI Wei, YE Shou-dong, LIU Da-hai. Gadd45g Induces Mesendodermal Differentiation in Mouse Embryonic Stem Cells[J]. China Biotechnology, 2017, 37(4): 9-17.

[5]	LI Zhen-hua, LI Cui-ping, ZHANG Xiang-qiang, DAI Li-ting, TANG Meng-si, WANG Guo-cai, JIANG Jian-wei, CAO Ming-rong. EM-3 Targets Stat3 to Induce Apoptosis, G₂/M Cell Cycle Arrest and Reduce the Proportion of SP Cells in Nasopharyngeal Carcinoma[J]. China Biotechnology, 2016, 36(3): 1-10.

[6]	MENG Shu-lin, MA Bu-yun, ZHANG Xin-min, GE Yun, ZHANG Rong, HUANG Pan-pan, WANG Yi-gang. Killing Effects of Thioridazine on Liver Cancer Stem Cell[J]. China Biotechnology, 2015, 35(2): 8-17.

[7]	LI Yan-hong, LI Xiao-bo, LU Xue-ying, GAO Jian-feng, XIAO Xiang-wen. Immunoadjuvant Effect of Ursolic Acid for Murine H22 Hepatocarcinoma Cell Vaccine[J]. China Biotechnology, 2013, 33(10): 28-35.

[8]	QIN Xiao-lin, XU Yong, FAN Xiao-qing, LI Wu-xian, KUANG Wen-bin, CHENG eng, TU Zhi-guang. Effects of TFPI-2 on Proliferation, Apoptosis and AFP Expression of Hepatocarcinoma Cells[J]. China Biotechnology, 2011, 31(12): 33-38.

[9]	WEI Li-li, LI Run-ce, QIANG Rong-bing, ZHANG Nan-nan, LIU Yue-yue, ZHANG Guo-fang, YANG Mei, HOU Ying-chun. Effects of ANXA2 on Biological Behaviour of Human Hepotacellular Carcinoma in Vitro[J]. China Biotechnology, 2010, 30(11): 11-16.

[10]	XU Liang, GU Yu-Chao, SHI Han, FU Wen-Xi, XU Wen-Gong. STAT3 Silencing Inhibits Migration of Murine Breast Cancer Cells in vitro[J]. China Biotechnology, 2010, 30(06): 1-7.

Viewed

Full text

Abstract

Cited

Shared

Discussed